SEHK:2171Biotechs
Assessing CARsgen Therapeutics Holdings’ Valuation After 2025 Earnings Guidance Points To Smaller Net Loss
CARsgen Therapeutics Holdings (SEHK:2171) issued preliminary 2025 earnings guidance indicating a sharp year on year reduction in net loss, driven by commercial activity, lower research costs, and foreign exchange effects.
See our latest analysis for CARsgen Therapeutics Holdings.
CARsgen Therapeutics Holdings’ latest guidance lands after a volatile stretch, with a 6.32% 1 day share price return to HK$14.13 following recent weakness, including a 13.74% 30 day share price decline. The 1 year...